Stay updated on Pemigatinib Dose-Escalation Clinical Trial
Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedGastric cancer was added to the list of conditions for the study. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision: v3.4.1 replaces v3.4.0 on the page, a minor version update that does not affect study content or navigation. No substantive study information changes were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedAdded: Show glossary, 'Last Update Submitted that Met QC Criteria', No FEAR Act Data, and Revision: v3.4.0; Deleted: 'Last Update Submitted that met QC Criteria' (lowercase met), No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision: v3.3.4 added; previous v3.3.3 removed; no visible content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedLocations were added for AL, CA, CT, DC, FL, GA, MI, MO, NJ, NY, NC, OH, SC, and TX; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.9%

- Check91 days agoChange DetectedPublications section now states that entries are automatically filled from PubMed and may not all pertain to the study, and the page revision tag changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.